NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

• Asıl Yazarlar: Helene Cawston (Yazar), Francois Bourhis (Yazar), Jennifer Eriksson (Yazar), Pierfrancesco Ruffo (Yazar), Paolo D'Agostino (Yazar), Marco Turini (Yazar), Lee Schwartzberg (Yazar), Alistair McGuire (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BioExcel Publishing Ltd, 2017-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...